The NIAID funded UTMB Clinical Proteomics Center's objective is to discover, qualify, and verify candidate protein biomarkers relevant to infectious diseases caused by NIAID Category A-C pathogens and emerging and re-emerging infectious disease pathogens. Candidate biomarkers may be of pathogen or infected host origin.
Our intent is to enable collaborating investigators with methods to identify predictive biomarker panels of outcome or therapeutics in humans with NIAID Category A-C pathogens or new/emerging infectious pathogens.
Projects are submitted on-line as brief Pre-proposals for Center and NIAID review. Approved Pre-proposals are collaboratively developed into full Proposals for external Scientific review (six leading experts from the scientific community) and NIAID approval. Samples and data are then transferred to the center for analysis.
We then provide:
How to engage us
We are available at any time to consult with interested researchers regarding their project Pre-proposal to discuss optimal study design, endpoint
identification and sample preparation. Please send an email to Dr. Allan Brasier. Pre-proposals are submitted via this
website. Go to Pre-proposal Submission.